🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06824129
Active, not recruiting Observational

Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR

NCT06824129 · tracked via the Priya Life Science UK tracker
Sponsor
QIAGEN Gaithersburg, Inc
Phase
Observational
Started
2025-12-23
Last updated
2026-07-29

Condition(s) studied

Complicated Urinary Tract Infection

Study summary

Performance evaluation of QIAstat-Dx cUTI Plus AMR Panel using the QIAstat-Dx® Analyzer to demonstrate that the QIAstat-Dx cUTI Plus AMR Panel achieves its intended performance during normal conditions of use by the intended user in the intended environment

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * Specimens from subjects of all ages and demographic characteristics can be enrolled. * Specimen must come from patients with suspected cUTI by their healthcare provider: * Urine specimen with evidence of pyuria confirmed by positive urine analysis (Dipstick analysis positive for leukocyte esterase or at least 10 White Blood Cells percubic millimeter) And * A sign or symptom of a cUTI (for example: chills or rigors or warmth associated with fever, malaise, flank pain or pelvic pain and/or costo-vertebral angle pain or tenderness on physical examination, nausea or vomiting, dysuria, urinary frequency or urinary urgency) * Specimen must be residual leftover and de-identified * Specimen obtained preserved (containing boric acid, sodium formate or sodium borate) or unpreserved as midstream urine or fresh urine catheter * For Preserved Only: Fresh prospectively collected preserved specimens stored to up 48 hours at 15°C-25°C or 24 hours at 2°C-8°C. * For Unpreserved Only: Fresh prospectively collected unpreserved specimens stored up to 24 hours at 2°C-8°C. * Specimen must have a minimum of 3 ml of urine available. * Specimen date of collection and standard of Care testing results should be available. * Specimen must be unique (only one sample enrolled per patient). Exclusion Criteria: * Specimens enrolled in the study may be excluded for the following reasons: * Lack of clear subject identification or label on urine specimen. * Specimen has been centrifuged. * Obvious physical damage of residual specimen.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
QIAGEN Manchester United Kingdom

More QIAGEN Gaithersburg, Inc trials in the UK

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06824129 on ClinicalTrials.gov ↗ ← All trials in the UK